That the big pharmaceutical company's business model is having to undergo a major structural change seems beyond argument. By any standards, the model is broken and is failing to deliver for the shareholders, pharmaceutical employees and, most importantly, their patients. The pressure for change has become inescapable and the effects of the changes are all too visible here in the UK, as one large pharma after another has announced downsizing, restructuring and site closures.

This content is only available as a PDF.